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LETTERS TO THE EDITOR
Supplementary data to the
study of ESRD Map in Japan
To the Editor: Our recent study [1] has added more
convincing evidence for renoprotection of angiotensin-
converting enzyme inhibitors (ACEIs) by asking whether
the use of ACEIs may explain our previously disclosed
important findings [i.e., regional variations in incidence
of end-stage renal disease (ESRD)] in Japan [2]. In this
study, we used the amounts of expense spent on ACEIs
as an explanation. This was, however, a surrogate marker
for a real use of ACEIs. Therefore, we next retrieved data
regarding the real use of ACEIs from Nephro-Database
in one large nephrology care center in Japan (Kimitsu
Hospital) [3]. The rationale for using this database was
that the hospital was the only nephrology center in its
catchment area, excluding patients and hospital-based
bias, and, more importantly, that the age-, sex- and under-
lying disease-adjusted cumulative incidence of ESRD was
significantly higher than other areas in Japan, for example,
in 1997, 178.9 per 1 million in the area, and 127.1 in Japan
as a whole, allowing us to compare ACEIs with other
potential risk factors in the area where progression of
renal failure was far accelerated. We conducted a retro-
spective chart review of 74 consecutive patients who had
started renal replacement therapy (RRT) between Janu-
ary 1993 and December 2000. Multiple logistic regression
Table 1. Multivariate logistic regression analysis of risk factors
associated with inception of renal replacement therapy
Odds ratio
Risk factors (95% CI) P
Sex (vs. female) 1.3 (1.1–2.1) 0.04
Age (vs. 40) 1.3 (1.0–2.8) 0.04
Late referral (vs. no)a 3.4 (1.4–3.6) 0.003
Baseline data
Serum creatinine (vs. 1.3 mg/dL) 2.1 (1.1–2.3) 0.004
Proteinuria level (vs. 1 g) 1.7 (1.9–2.5) 0.013
Hypertension (vs. no)b 2.4 (1.1–3.2) 0.004
Management
Anemia (vs. not on erythropoietin) 1.6 (1.2–2.1) 0.02
Use of ACEI as antihypertensive agents
(vs. below recommended dose) 0.5 (0.3–0.7) 0.003
Diet adherence (vs. good)c 1.3 (1.8–4.6) 0.03
a Late referral was defined as a case that started renal replacement therapy
within six months after an initial consult to renal outpatient clinic in the Kimitsu
Hospital
b Patients who had sitting systolic of diastolic blood pressure over 140/90
mm Hg, or who were receiving antihypertensive drugs were judged hypertensive
c Dietary adherence (good adherence was defined as daily urinary protein
intake less than 0.7 g and sodium intake less than 7 g, otherwise allocated to
poor adherence)
1920
analysis clearly demonstrated an independently favorable
role of “a usage of ACEIs (dose over the least officially
recommended one)” against inception of RRT among
antihypertensive agents (Table 1). Thus, we could confirm
the conclusion [1] in a local area of Japan on a micro
level, as well.
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Stopping progression
in familial juvenile
hyperuricemic nephropathy
with benzbromarone?
To the Editor: In a recent issue of Kidney International,
a landmark paper on familial juvenile hyperuricemic ne-
phropathy (FJHN) was published. Bleyer et al [1] describe
a large family with the disease, which is caused by a uromo-
dulin gene mutation. Chronic and progressive renal failure
was the most prominent clinical feature. Despite treat-
ment with allopurinol, loss of creatinine clearance (CrCl)
exceeded 3 mL/min/year.
Hyperuricemia in FJHN is caused by reduced fractional
excretion of uric acid (FEUA). Whereas allopurinol does
not affect FEUA, benzbromarone normalizes it in FJHN
[2]. We treated two FJHN patients with a combination of
allopurinol adjusted to renal function and benzbromarone
Letters to the Editor 1921
100 mg a day for 68 months. The patients, a mother and
son, had a heterozygous 481T→C mutation in the uromo-
dulin gene, causing a C126R amino acid change predicted
to disrupt the tertiary structure of Tamm-Horsfall glyco-
protein [3]. The mother, age 53, had a CrCl of 38 mL/
min, which decreased to 16 mL/min within one year. After
introduction of benzbromarone 100 mg her renal function
stabilized and her actual CrCl was 17 mL/min. The 32-
year-old son had a CrCl of 58 mL/min. His renal function
also remained stable under benzbromarone 100 mg, with
an actual CrCl of 60 mL/min. We think that a trial of
benzbromarone is justified in patients with FJHN. If benz-
bromarone proves to be effective this would also imply
that reduced FEUA is of pathogenetic importance. There
is nothing to be lost, but possibly much to win using benz-
bromarone in FJHN.
Karl Lhotta
Innsbruck, Austria
Correspondence to Karl Lhotta, M.D., Division of Clinical Nephrol-
ogy, Dept. of Internal Medicine, Innsbruck University Hospital, Anich-
strasse 35, A-6020 Innsbruck, Austria.
E-mail: Karl.Lhotta@uibk.ac.at
REFERENCES
1. Bleyer AJ, Woodard AS, Shihabi Z, et al: Clinical characterization
of a family with a mutation in the uromodulin (Tamm-Horsfall glyco-
protein) gene. Kidney Int 64:36–42, 2003
2. Lhotta K, Gruber J, Sgonc R, Fend F, Ko¨nig P: Apoptosis of
tubular epithelial cells in familial juvenile gouty nephropathy. Neph-
ron 79:340–344, 1998
3. Turner JJO, Stacey JM, Harding B, et al: Uromodulin mutations
cause familial juvenile hyperuricemic nephropathy. J Clin Endocrinol
Metab 88:1398–1401, 2003
Submaximal dose of
trandolapril in the
COOPERATE trial?
To the Editor: In the recent study published in Kidney
International by Jacobsen et al [1], the authors considered
the dose of angiotensin-converting enzyme inhibitor used
in the COOPERATE trial [2] to be submaximal. With
regard to this issue, however, we disagree with the authors.
Trandolapril at a dose of 3 mg is sufficient. First, the base-
line renal function of the enrollee was moderately re-
duced (mean serum creatinine level, 265 12.5 mmol/L).
In Japan, the recommended maximum dose of trandola-
pril is 2 mg, mainly for patients with uncomplicated es-
sential hypertension. Thus, pharmacies strongly request
us to reduce the dose in patients with renal dysfunction.
Second, during a run-in period, we had confirmed the
individual maximal anti-proteinuric efficacy of trandola-
pril using an up-titration scale from 0.5 to 6.0 mg. Of
301 patients, 240 showed dose-response reactions up to
3 mg. Above this dose, however, no additional anti-
proteinuric benefit was obtained. Third, the more a dose
was increased, the higher the tendency for side effects,
including hypotension, gastrointestinal symptoms, and
acute renal decline or low compliance of the patients.
Fourth, compared with the previous study asking the effi-
cacy of 4 mg trandolapril in chronic renal disease [3], the
anti-proteinuric efficacy obtained in the COOPERATE
was not less. Lastly, according to the official reports
of pharmacokinetic and pharmacodynamic variables of
trandolapril in Japanese patients with renal dysfunction
[4], these variables after 7 days’ consecutive use of even
1 mg are three times greater than those of patients with
congestive heart failure who have been treated with 4 mg
trandolapril.
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Reply from the Author
We appreciate the important additional information
from the COOPERATE trial [1] in the letter by Dr. Na-
kao regarding the dose of trandolapril used. We recognize
that 3 mg of trandolapril seems to be the optimal dose in
this Japanese population with nondiabetic renal disease.
This further supports the findings of an additional reno-
protective effect of treatment with both ACE inhibitors
(ACE-I) and angiotensin II receptor antagonists (ARB)
in patients with renal disease found in our own study of
diabetic nephropathy [2], as well as in the COOPERATE
trial [1]. However, it should be mentioned that the maxi-
mal recommended dose of trandolapril is 4 mg daily in
Europe and various renal diseases and ethnic groups [3]
have different degrees of renal and systemic activation of
